InnoCare Secures China Breakthrough Therapy Status for Marginal Zone Lymphoma Therapy
BEIJING, Aug. 4, 2026 InnoCare Pharma announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation...
CDE
Advertisement
Avance Clinical Unveils Asia Growth Strategy at BIO Asia–Taiwan
TAIPEI, Taiwan | July 10, 2026 Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO), has announced its participation...
Leads Biolabs Secures Priority Review for Opamtistomig
NANJING, China | July 10, 2026 Nanjing Leads Biolabs Co., Ltd. has announced that the Center for Drug Evaluation...
Aligos Secures $25M Upfront in Greater China Deal
SOUTH SAN FRANCISCO, Calif., July 6, 2026 Aligos Therapeutics has received a $25 million upfront payment from Xiamen Amoytop...
Ribo’s RBD1119 Moves Into Phase 2 Development for Coronary Artery Disease
SUZHOU, China, May 29, 2026 Suzhou Ribo Life Science and Ribocure Pharmaceuticals (collectively “Ribo”) have announced the submission of...
Advertisements
Antengene Expands Oncology Pipeline With Phase III ATG-022 Gastric Cancer Trial
SHANGHAI and HONG KONG, China, May 28, 2026 Antengene has announced a major clinical development milestone after receiving endorsement...
InnoCare Wins China NDA Acceptance for Orelabrutinib in ITP
BEIJING — May 28, 2026 InnoCare Pharma announced that China’s Center for Drug Evaluation (CDE) under the National Medical...
Advertisement
